Searched for
CEPHALOSPORIN API
Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: ReportA Systematix Research report indicates the Indian pharmaceutical industry is navigating uncertainty due to US tariffs, necessitating price ...- Orchid Pharma shares in focus as U.S. FDA completes facility inspectionOrchid Pharma share price: Orchid Pharma's Alathur facility is the only U.S. FDA-approved manufacturing site in India for sterile cephalosp...
- China hikes prices of key drug ingredientsWhile increased prices will put cost pressure on the domestic industry over the next few months, more importantly it has sparked speculatio...
- China supplies over 80% of pharma raw materialsThe India-China border standoff has put the spotlight back on our near-total dependence on the dragon for crucial raw materials used in med...
- Icra revises domestic pharma industry outlook to negative due to coronavirus outbreakIt has revised its outlook due to ongoing lockouts in China following the outbreak of coronavirus.
- USFDA makes 22 observations post inspection of Lupin's Mandideep facilitiesLupin said the observations are "largely procedural in nature with some gaps identified in the aseptic processing areas of the Cephalospori...
- Curb imports of APIs to boost local production, says task force on pharmaIncreasing indigenous production of APIs would ensure availability of drugs fighting country’s rising disease burden, it said.
- German ban on Ranbaxy's Dewas product expands to entire EUAdding to Ranbaxy's regulatory troubles overseas, certain drugs produced at its Dewas plant have been barred from export to all member coun...
- US based Hospira to buy Orchid's API manufacturing, R&D units in $200 million dealOrchid Chemicals today said it will sell various assets including active pharmaceutical ingredients (API) business and a R&D facility to Ho...
- Parabolic Drugs a good bet for long-term playShares of Chandigarh-based Parabolic Drugs - a manufacturer of active pharmaceutical ingredients, or APIs, which got listed in July 2010 - ...
- Lupin gets final US FDA nod for generic anti-epileptic drugLupin is the 5th largest generics player in the US (by prescriptions), the only Asian company to achieve that distinction.
- Operations at Orchid's Alathur unit comes to haltOrchid Chemicals & Pharmaceuticals Ltd has temporality closed down its Cephalosporin API manufacturing facility in Chennai.
- Orchid Chemicals, Pharmaceuticals Ltd clear USFDA inspectionOrchid Chemicals and Pharmaceuticals Ltd has said its Cephalosporin API manufacturing (antibiotic) complex in Alathur, Chennai, has success...
- Orchid Chemicals gains post USFDA inspectionOrchid Chemicals & Pharmaceuticals’ manufacturing facility at Alathur, Chennai has been re-inspected by the USFDA.
- Parabolic Drugs IPO opens on June 14Parabolic Drugs will enter the primary market on June 14, 2010 to raise Rs 200 crore through its initial public offer.
- Lupin gets FDA nod for Levetiracetam TabletsDomestic drug maker Lupin on Friday announced that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received the final approval for...
- Wockhardt gets USFDA approval for Ceftazidime injectionCeftazidime is the generic name for the brand Fortaz, sold in the US by Glaxo Smithkline.
- Religare assigns 'buy' to Nectar Lifesciences; target Rs 503Religare Securities has recommended 'buy' on Nectar Lifesciences with a target price Rs 503.
- Citi Venture picks up 30% in UnimarkUS-based PE fund Citi Venture Capital has picked up 30% stake in Mumbai-based bulk drug maker Unimark Remedies for Rs 113 crore.
- Parabolic Drugs to invest Rs 100 cr on new unitsPharmaceuticals firm Parabolic Drugs Ltd (PDL) plans to infuse Rs 100 crore on setting up new facilities in Punjab and Himachal Pradesh as ...
Load More
